Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug
development remains challenging, with high costs, long pathways to clinical use and high …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of adult life, causing
weakness and wasting of voluntary muscles, associated in about 50% of cases with a …

Amyotrophic lateral sclerosis (ALS) involves progressive motor neuron loss, leading to
paralysis and death typically within 3–5 years of diagnosis. Dysfunctional astrocytes may …

Compelling evidence from experimental animal disease models and early-phase clinical
trials identifies the transplantation of neural progenitor/stem cells (NSCs) as a viable path …

Neurodegenerative diseases (ND) are an entire spectrum of clinical conditions that affect the
central and peripheral nervous system. There is no cure currently, with treatment focusing …

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease
characterized by the loss of motor neurons and neuromuscular impairment leading to …

Due to the ability to differentiate into variety of cell types, mesenchymal stem cells (MSCs)
hold promise as source in cell-based therapy for treating injured tissue and degenerative …

Background: Mesenchymal stem cells (MSC) were shown to induce beneficial effects in
animal models of neurodegeneration and in pilot human trials in multiple sclerosis and …

Numerous potential amyotrophic lateral sclerosis (ALS)‐relevant pathways have been
hypothesized and studied preclinically, with subsequent translation to clinical trial. However …

Amyotrophic lateral sclerosis (ALS) is an extremely heterogeneous disease of motor
neurons that eventually leads to death. Despite impressive advances in understanding the …